These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 209809)

  • 1. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misonidazole Neuropathy: a clinical, electrophysiological, and histological study.
    Melgaard B; Hansen HS; Kamieniecka Z; Paulson OB; Pedersen AG; Tang X; Trojaborg W
    Ann Neurol; 1982 Jul; 12(1):10-7. PubMed ID: 7114817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathy in myotonic dystrophy: a nerve biopsy study.
    Cros D; Harnden P; Pouget J; Pellissier JF; Gastaut JL; Serratrice G
    Ann Neurol; 1988 May; 23(5):470-6. PubMed ID: 2839105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropathy caused by cisplatin. Clinical, electrophysiological and morphological study].
    Gastaut JL; Pellissier JF
    Rev Neurol (Paris); 1985; 141(10):614-26. PubMed ID: 3003868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroneurographic investigations of misonidazole polyneuropathy.
    Mamoli B; Wessely P; Kogelnik HD; Müller M; Rathkolb O
    Eur Neurol; 1979; 18(6):405-14. PubMed ID: 232682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyneuropathy. Facts and fancies.
    Buchthal F; Behse F
    Electroencephalogr Clin Neurophysiol Suppl; 1978; (34):373-83. PubMed ID: 220006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carcinomatous neuropathy: clinical and pathologic findings of sural nerve biopsy in 7 cases].
    Guo YP
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):216-9, 253-4. PubMed ID: 2559834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin neuropathy: structural changes in the sural nerve.
    Ramirez JA; Mendell JR; Warmolts JR; Griggs RC
    Ann Neurol; 1986 Feb; 19(2):162-7. PubMed ID: 3008637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiological approach to peripheral neuropathy. Conventional nerve conduction studies and magnetic motor root stimulation].
    Ugawa Y
    Rinsho Shinkeigaku; 2004 Nov; 44(11):986-90. PubMed ID: 15651350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.